Ascendis Pharma A/S (ASND) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $230.01 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Consecutive earnings misses (2).
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency;... Read more
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $230.01 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Consecutive earnings misses (2). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $230.01 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Consecutive earnings misses (2). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $214.95. Score 5.4/10, moderate confidence.
Take-profit target: $253.34 (+10.1% upside). Prior stop was $214.95. Stop-loss: $214.95.
Consecutive earnings misses (2); Negative momentum.
Ascendis Pharma A/S trades at a P/E of N/A (forward 25.6). TrendMatrix value score: 4.5/10. Verdict: Sell.
24 analysts cover ASND with a consensus score of 4.4/5. Average price target: $298.
What does Ascendis Pharma A/S do?Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for...
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.